Novartis gets creative in pricing next-generation cancer therapy
Its medicine is for a severe form of cancer in young people, known as acute lymphoblastic leukaemia
Fri, Jun 09, 2017 - 5:50 AM
NOVARTIS AG, set to beat Kite Pharma Inc to the finish line in one of the most promising new areas of cancer research, is examining how to price a revolutionary therapy patients will need to take just once.
The US Food and Drug Administration is likely to rule in early...